C Crotti F Zucchi C Alfieri R Caporali M Varenna
10.1007/s00198-022-06516-6
Osteoporos Int
2023 Jan;34(1):201-206.
burosumab fgf23 osteomalacia tumor-induced bone disease
NO-CC CODE
https://pubmed.ncbi.nlm.nih.gov/35925260/
COVID-19 / complications Hypophosphatemia / drug therapy Hypophosphatemia / etiology Hypophosphatemia / pathology Osteomalacia / drug therapy Osteomalacia / etiology Paraneoplastic Syndromes / drug therapy Paraneoplastic Syndromes / etiology
COVID-19 / complications Hypophosphatemia / drug therapy Hypophosphatemia / etiology Hypophosphatemia / pathology Osteomalacia / drug therapy Osteomalacia / etiology Paraneoplastic Syndromes / drug therapy Paraneoplastic Syndromes / etiology Case Reports Antibodies, Monoclonal, Humanized / therapeutic use Female Fibroblast Growth Factors Humans Middle Aged Phosphates burosumab Antibodies, Monoclonal, Humanized Fibroblast Growth Factors Phosphates Oncogenic osteomalacia
PMC9361946
35925260
Long-term use of burosumab for the treatment of tumor-induced osteomalacia
2023